Table 3 Study outcomes according to surgical prophylaxis exposure

Primary outcomes

30 (65)

14 (58)

16 (73)

0.364

Secondary outcomes

 Infections by ESBL/MDR GN bacteria, n (%)

15 (33)

4 (17)^h

11 (50)^h

0.027

 Colonizations by ESBL/MDR GN bacteria, n (%)

15 (33)

10 (42)

5 (23)

0.212

Other outcomes

 Infection by MS GN bacteria, n (%)

2(4)

1(4)

2(5)

0.999

 Infection by GP bacteria, n (%)

6 (13)

2 (8)

4 (18)^l

0.405

 Invasive mechanical ventilation, hours

24 [20–59]

24 [19–64]

24 [20–59]

0.125

 Re-tracheal intubation and/or tracheostomy, n (%)

10 (22)

2 (8)

8 (36)

0.032

 Anastomotic complications, n (%)

4 (9)

2 (8)

2 (9)

0.999

 30-day acute rejection^g, n (%)

11 (24)

8 (33)

3 (14)

0.171

 ICU LOS, days

7 [5–17]

6 [3–14]

8 [6–23]

0.002

 Hospital LOS, days

33 [30–45]

33 [30–38]

35 [31–50]

0.039

 Hospital mortality, n (%)

3 (7)

0 (0)

3 (14)

0.101

 ECMO post-surgery, n (%)

5 (11)

3 (13)

2 (9)

0.999

 PGD at 72 h

1 [0–2]

1 [0–1]

1 [0–2]

0.286

 Immunosuppressive therapy (cyclosporine (ref))^m

30 (65)

13 (54)

17 (77)

0.129

 Renal replacement therapy, n (%))

6 (13)

2 (8)

4 (19)

0.405